<DOC>
	<DOCNO>NCT02516267</DOCNO>
	<brief_summary>The purpose study assess platelet aggregability `` point care '' device ( Multiplate® ) decrease release time coronary artery bypass graft ( CABG ) patient acute coronary syndrome ( ACS ) use dual antiplatelet therapy .</brief_summary>
	<brief_title>Evaluation Platelet Aggregability Release CABG Patients With ACS With DAPT .</brief_title>
	<detailed_description>This open , prospective , randomize study include patient acute coronary syndrome ( ACS ) coronary artery bypass graft ( CABG ) indication use double platelet aggregation ( aspirin inhibitor ADP ) . The group analyze : 1 . Control group : It compose patient discontinue inhibitor ADP 5 day surgery , must operate first work day complete 5 day without drug . This group aggregability evaluate platelet function test ( Multiplate® ) immediately transport operating room . 2 . Intervention group : It compose patient evaluated platelet function test ( Multiplate® ) daily value obtain &gt; 46 AU , immediately release CABG , hold first working day release . All patient include , explanation sign informed consent , initially undergo preoperative examination institutional routine . In immediate period ( 24 hour ) CABG collect result test patient submit accordance institutional routine , volume chest tube bleed need blood transfusion . Clinical data `` MACE '' collect throughout patient 's hospital stay .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>1 . Age &gt; 18 year ; 2 . Hospitalization ACS define : Symptoms ischemic unstable pattern , occur rest upon exertion within 72 hour unscheduled hospitalization , relate presume proven coronary artery , least one following : elevated cardiac biomarkers ( troponin I CKMB mass ) 99th percentile . Changes rest electrocardiogram compatible ischemia infarction evidence obstructive coronary artery disease : resting ECG compatible ischemia infarction least one criterion : ST segment depression new presumably new &gt; 0.5 mm 2 sequential lead . The new STsegment elevation presume new J point two contínguas lead value &gt; 0.2mV men &gt; 0.15mV woman V2V3 / &gt; 0.1mV lead new leave bundle branch block presumably . T wave inversion new presumably new &gt; 1mm lead broad R wave two contiguous lead . New pathological Q wave presumably new &gt; 30 ms duration &gt; 1mm deep 2 contiguous lead &gt; 20 ms QS complex V2 V3 . Peaked new R Wave &gt; 40 m V1 V2 , R / S &gt; 1 V1 positive T wave absence consistent drive change . Additional evidence coronary artery disease least one criterion : Evidence myocardial ischemia new presumably new image perfusion . Contractility Change new presumably new wall . Coronary angiography obstruction &gt; 70 % epicardial coronary artery . 3 . Use dual antiplatelet therapy ( ASA associate P2Y12 receptor inhibitor ) ; 4 . An indication CABG . 5 . Agreement sign Informed Consent ( IC ) ; Exclusion criterion : 1. anemia ( hematocrit &lt; 30 % ) . 2 . Thrombocytopenia ( &lt; 100,000 / mm³ ) . 3 . Coagulopathy ( history bleed diathesis use oral anticoagulant ) . 4 . Chronic renal failure dialysis creatinine clearance &lt; 30 ml / min / m2 ( estimate MDRD formula ) . 5 . Active liver disease . 6. combined valvuloplasty valve replacement surgery .. 7 . Angioplasty stent le 30 day drugeluting stent less one year . 8 . Use fibrinolytic specific fibrin le 48 hour specific fibrin less 24 hour randomization ; 9 . Any medical condition investigator 's opinion present significant risk patient interfere interpretation safety efficacy ; 10 . Patients take part another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>platelet aggregability</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>coronary artery bypass graft</keyword>
</DOC>